Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:26 AM
Ignite Modification Date:
2025-12-25 @ 3:26 AM
NCT ID:
NCT05856305
Eligibility Criteria:
Inclusion Criteria:
* Age \> 18 years.
* Histologically confirmed diagnosis of adenocarcinoma of the rectum.
* Clinical Stage II/III (T2-3, 4b: adherent to prostate, SV or post vagina but not grossly invading, N0-2) based on MRI.
* Non-circumferential tumours with craniocaudal length \<7 cm
* The tumours of the lower rectum, or starting up to 7 cm from the anal verge.
* No evidence of distant metastases on CT Chest and Abdomen.
* No prior pelvic radiation therapy
* No prior chemotherapy or surgery for rectal cancer
* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
* Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.
* Eligible to receive one of the options of standard neoadjuvant chemotherapy as determined by the medical oncologist team.
* Absolute neutrophil count (ANC) \> 1.5 cells/mm3, hemoglobin (HGB) \> 8.0 gm/dl, platelet (PLT) \> 150,000/mm3.
* Total bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's Syndrome who must have total bilirubin ≤ 3.0 x ULN), aspartate aminotransferase (AST) ≤ 3 x ULN, alanine transaminase (ALT) ≤ 3 x ULN.
Exclusion Criteria:
* Signet or mucinous histology cancer of rectum
* Recurrent rectal cancer or previous pelvic radiotherapy
* Primary unresectable rectal cancer.
* Creatinine level greater than 1.5 times the upper limit of normal.
* Patients who are unable to undergo an MRI.
* Patients with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), MI, TIA, or CVA.
* Ulcerative colitis or any other histologically confirmed inflammatory bowel disease.
* Patients with a history of venous thrombotic episodes such as deep venous thrombosis, and pulmonary embolism occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, patients who are anticoagulated for a trial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.
* Poor reliability for follow up.
* Ineligible as per eligibility criteria
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
90 Years
Study:
NCT05856305
Study Brief:
Protocol Section:
NCT05856305